Conquering influenza: Recent advances in anti-influenza drug discovery

IDrugs

Volumn 2, Issue 7, 1999, Pages 671-685

  Luo, Guangxiang ^a   Cianci, Christopher ^a   Harte, William ^a   Krystal, Mark ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 ACETAMIDO 3 GUANIDINOBENZOIC ACID; 4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; AMANTADINE; ANTIVIRUS AGENT; FOSCARNET SODIUM; INFLUENZA VACCINE; ION CHANNEL INHIBITOR; MATRIX PROTEIN; OSELTAMIVIR; RIMANTADINE; RNA POLYMERASE INHIBITOR; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS HEMAGGLUTININ INHIBITOR; VIRUS SIALIDASE; ZANAMIVIR;

DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; GASTROINTESTINAL SYMPTOM; HUMAN; INFLUENZA; INFLUENZA VIRUS; INHALATIONAL DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; REVIEW;

EID: 0032977641     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (152)

1. Murphy BR. Webster RG: Orthomyxoviruses. In: Virology, Fields BN, Knipe DM, Howley PM (Eds), Raven Press, New York(1996):1397-1445.
2. Couch RB: A new antiviral agent for influenza - is there a clinical niche? NewEngl JMed(1997) 337:927-928.
3. Subbarao K, Klimov A, Katz J, Regnery H, Um W, Hall H, Perdue M, Swayne D, Bender C, Huang J, Hemphill M, Rowe T, Shaw M. Xu X, Fukuda K, Cox N: Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science (1998) 279:393-396.
4. Suarez DL, Perdue ML, Cox M, Rowe T, Bender C, Huang J, Swayne DE: Comparisons of highly virulent H5N1 influenza A viruses isolated from humans and chickens from Hong Kong. J V7ro/(1998) 72:6678-6688.
5. Webster RG: Influenza: an emerging disease. Emerg Infect Dis (1998) 4:436-441.
6. Hirsch MS, Kaplan JC, D'Aquila RT: Antiviral agents. In: Virology, Relds BN, Knipe DM, Howtey PM (Eds), Raven Press, New York (1996):431-466.
7. Hayden FG, Hay AJ: Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine. Curr Top Microbiol Immunol (1992) 176:119-130.
8. Couch RC, Keitel WA, Cate TR: Improvement of inactivated influenza virus vaccines. J Infect Dis (1997) 176(Suppl 1):S38-S44.
9. Hayden FG. Osterhaus AD, Treanor JJ, Fleming DM, Aoki FY, Nicholson KG, Bohnen AM, Hirst HM, Keene O, Wightman K: Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections. New Engt J Med (1997) 337:874-880.
10. The first clinical study conducted in multiple centers demonstrating the clinical efficacy and safety of a neuraminidase inhibitor (zanamivir) for the treatment of influenza.
11. Calfee DP, Hayden FG: New approaches to influenza chemotherapy. Neuraminidase inhibitors. Drugs (1998) 56:537-553.
12. Oxford JS, Lambkin R: Targeting influenza virus neuraminidase - a new strategy for antiviral therapy. Drug Disc Today (1998) 3:448-456.
13. Hayden FG: Antivirals for pandemic influenza. J Infect Diseases (1997) 176(Suppl 1):S56-S61.
14. Carr CM, Kim PS: A spring-loaded mechanism for the conformations! change of influenza hemagglutinin. Cell (1993)73:823-832.
15. Bullough PA, Hughson FM, Skehel JJ, Wiley DC: Structure of influenza haemagglutinin at the pH of membrane fusion. Nature (1994) 371:37-43.
16. Bodian DL, Yamasaki RB, Buswell RL, Steams JF, White JM, Kuntz ID: Inhibition of the fusion-inducing conformational change of influenza hemagglutinin by benzoquinones and hydroquinones. Biochemistry (I993) 32:2967-2978.
17. Luo GX, Colonno R, Krystal M: Characterization of a hemagglutinin-specific inhibitor of influenza A virus. Virology (1996) 226:66-76.
18. I 17. Luo GX. Torri A, Harte WE, Danetz S, Cianci C, Tiley L. Day S, Mullaney D, Yu KL, Quellet C, Dextraze P, Meanwell N, Colonno R, Krystal M: Molecular mechanism underlying the action of a novel fusion inhibitor of influenza A virus. J Virol (1997) 71:4062-4070.
19. Hoffman LR, Kuntz IS, White JM: Structure-based identification of an induccr of the low-pH conformational change in the influenza virus hemagglutinin:irreversible inhibition of infectivity. J V7ro/(1997) 71:8808-8820.
20. Staschke KA, Hatch SD, Tang JC, Homback WJ, Munroe JE, Colacino JM, Muesing MA: Inhibition of influenza virus hemagglutinin-mediated membrane fusion by a compound related to podocarpic acid. Virology (1998) 248:264-274.
21. Plotch SJ, O'Hara B, Morin J, Palant O, LaRoque J, Bloom JD, Lang Jr SA, CiGrandi MJ, Bradley M, Nilakantan R, Gluzman Y: Inhibition of influenza A virus replication by compounds interfering with the fusogenic function of the viral hemagglutinin. J V/ro/(1999) 73:140-151.
22. Kurtz S, Luo GX, Hahnenberger KM, Brooks C, Gecha O, Ingalls K, Numata Kl, Krystal M: Growth impairment resulting from expression of influenza virus M2 protein in Saccharomyces cerevisiae: Identification of a novel inhibitor of influenza virus. Antimicrob Agents Chemother (1995)39:2204-2209.
23. Tu Q, Pinto LH, Luo GX, Shaughnessy MA, Mullaney D, Kurtz S, Krystal M, Lamb RA: Characterization of inhibition of M2 ion channel activity by BL-1743, an inhibitor of influenza A virus. J V/ro/(1996) 70:4246-4252.
24. Scholtissek C, Quack G, Klenk HD, Webster RG: How to overcome resistance of influenza A viruses against adamantane derivatives. Antiviral Res (1998) 37:83-95.
25. Lin Tl, Heider H, Schroeder C: Different modes of inhibition by adamantane amine derivatives and natural polyamines of the functionally/reconstituted Influenza virus M2 proton channel protein. J Gen Virol (1997) 78:767-774.
26. Tomassini J, Seinick H, Davies ME, Armstrong ME, Baldwin J, Bourgeois M, Hastings J, Hazuda D, Lewis J, Mcclements W, Ponticello G, Radzilowski E, Smith G, Tebben A, Wolfe A: Inhibition of cap (m?GpppXm)-dependent endonuclease of influenza virus by 4-substituted 2,4-dioxobutanoic acid compounds. Antimicrob Agents Chemother (1994) 38:28272837.
27. Cianci C, Chung TOY, Meanwell N, Putz H, Hagen M, Colonno RJ, Krystal M: Identification of N-hydroxamic acid and N-hydroxyimide compounds that inhibit the influenza virus polymerase. Antiviral Chem Chemother (1996) 7:335360.
28. . 27. Lamb RA, Choppin PW: The gene structure and replication of influenza virus. Annu Rev Biochem (1983) 52:467-506.
29. Varghese JN, Laver WG, Cdman PM: Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 A resolution. Nature (1983) 303:35-40.
30. Colman PM, Varghese JN, Laver WG: Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature (1983) 303:41-44.
31. Varghese JN, McKimm-Breschkin JL, Caldewell JB, Kortl AA, Colman PM: The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor. Proteins (1992) 14:327-332.
32. Palese P, Tobita K, Ueda M, Compans RW: Characterization of temperature-sensitive Influenza virus mutants defective in neuraminidase. Virology (1974) 61:397-410.
33. Yang P, Bansal A, Liu CG, Air GM: Hemagglutinin specificity and neuraminidase coding capacity of neuraminidasedeficient influenza viruses. Virology (1997) 229:155-165.
34. Klenk HD, Rott R: The molecular biology of influenza virus pathogeniclty. Adv Virus Res (1988) 34:247-281.
35. Meindl P, Bodo G, Palese P, Schulman J, Tuppy H: Inhibition of neuraminidase activity by derivatives of 2-deoxy-2,3dehydro-N-acetylneuraminic acid. Virology (1974) 58:457463.
36. Palese P, Schulman JL, Bodo G, Meindl P: Inhibition of influenza and parainfluenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-N-trifluoroacetylneuraminic acid (FANA). Virology (1974) 59:490-498.
37. Burmeisler WP, Ruigrok RWH, Cusack S: The 2.2 A resolution crystal structure of influenza B neuraminidase and its complex with sialic acid. EMBO J(1992) 11:49-56.
38. Von Itzstein M, Wu WY. Kok GB, Pegg MS, Dyason JC, Jin B, Van Phan T, Smythe ML, White HF, Woods JM. Bethell RC, Hotham VJ, Cameron JM, Penn CR: Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature (1993) 363:418-423.
39. Kirn CD, Lew W, Williams MA, LJU HT, Zhang LJ, Swaminathan S, Bischofberger N. Chen MS, Mendel DB, Tai CY, Laver WG, Stevens RC: Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis and structural analysis of cabocyclic sialic acid analogues with potent anti-influenza activity. JAm Chem Soc (1997) 119:681-690.
40. Kirn CU, Lew W, Williams MA, Wu H, Zhang L, Chen X. Escarpe PA, Mendel DB, Laver WG, Stevens RC: Structureactivity relationship studies of novel carbocyclic influenza neuraminidase inhibitors. J Med Chem (1998) 41:2451 -2460.
41. Woods JM, Bethell RC, Coates JAV, Healy N, Hiscox SA, Pearson BA, Ryan DM, Ticehurst J, Tilling J, Walcott SM, Penn CR: 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro. Antimicrob Agents Chemother (1993)37:1473-1479.
42. Hayden FG, Rollins BS, Madren LK: Anti-influenza virus activity of the nnuraminidase inhibitor 4-guanidinoneu5Ac2en in cell culture and in human respiratory epithelium. Antiviral Res (1994) 25:123-131 (erratum appears in Antiviral Res (1994) 25:287.
43. Ryan DM, Tlcehuret J, Dempsey MH, Penn CR: Inhibition of influenza virus replication in mice by GG-167 (4-guanidino2,4-dideoxy-2,3-dehydro-N-acetylneuraminlc acid) is consistent with extracellular activity of viral neuraminidase (sialidase). Antimicrob Agents Chemother (1994) 38:2270-2275.Q
44. Thomas GP, Forsyth W, Penn CR, McCauley JW: Inhibition of the growth of Influenza viruses in vitro by 4-guanidino-2,4dideoxy-2,3-dehydro-N-acetylneuraminic acid. Antiviral Res (1994)24:351-356.
45. Ryan DM, Ticehurst J, Dempsey MH: GG-167 (4-guanidino-2,4dideoxy-2,3-dehydro-N-acetylneuraminic acid) is a potent inhibitor of influenza virus in ferrets. Antimicrob Agents Chemother (1995) 39:2583-2584.
46. Hayden FG, Treanor JJ, Betts RF, Lobo M, Esinhart JD, Hussey EK: Safety and efficacy of the neuraminidase inhibitor GG-167 in experimental human influenza. JAMA (1996) 275:295-299.
47. Walker JB, Hussey EK, Treanor JJ, Montalvo Jr A, Hayden FG: Effects of the neuraminidase inhibitor zanamivir on otologic manifestations of experimental human influenza J Infect Dis (1998)176:1417-1422.
48. Doyle WJ, Skoner DP, Alper CM, Alien G, Moody SA, Seroky JT, Hayden FG: Effect of rimantadine treatment on clinical manifestations and otologic complication in adults experimentally infected with influenza A (H1N1) virus. J Infect Dis (1998) 177:1260-1265.
49. Fenton RJ, Owens IJ, Mortey PJ: Chemoprophylaxis of influenza A infections in mice and ferrets with neuraminidase inhibitors exemplified by zanamivir (GG-167). Antiviral Res (1998)37:A72.
50. Monto AS, Robinson DP, Herlocher L, Hinson JM, Elliott M, Keene O: Efficacy and safety of zanamivir in prevention of influenza among healthy adults. /CMC (1998) 38: LB-7.
51. Carfee DP, Peng AW, Cass LMR, Lobo M, Hayden FG: Protective efficacy of intravenous zanamivir in experimental human influenza. ICAAC (1998) 38: H-58.
52. Mendel DB, Tai CY, Escarped PA, U W, Sidwell RW, Huffman JH, Sweet C, Jakeman KJ, Merson J, Lacy SA, Lew W, Williams MA, Zhang L, Chen MS, Bischofberger N, Kim CU: Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS-4071 protects mice and ferrets against influenza infection. Antimicrob Agents Chemother (1998)42:640-646.
53. Li W, Escarpe PA, Eisenberg EJ, Cundy KC, Sweet C, Jakeman KJ, Merson J, Lew W, Williams M, Zhang L, Kim CU, Bischofberger N, Chen MS, Mendel DB: Identification of GS4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS-4071. Antimicrob Agents Chemother (1998)42:647-653.
54. Eisenberg EJ. Bidgood A, Cundy KC: Penetration of GS-4071, a novel influenza neuraminidase inhibitor, into rat bronchoalveolar lining fluid following oral administration of the prodrug GS-4104. Antimcrob Agents Chemother (1997) 41:1949-1952.
55. Sidwell RW, Huffman JH. Barnard DL, Bailey KW, Wong MH. Morrison A, Syndergaard T. Kirn CU: Inhibition of Influenza virus infections in mice by GS-4104, an orally effective influenza virus neuraminidase inhibitor. Antiviral Res (1998) 37:107120.
56. Treanor JJ, Betts RF, Kallas E, Evans T. Hayden FG, Schultz-Cherry S, Miller M, Mills RG: Oral GS-4104 prevents experimental Infection of humans with influenza A (H1N1) virus. Int Conf Antiviral Res, (1998) 199.
57. Treanor JJ, Vrooman PS, Hayden FG, Kinnersley N, Ward P, Mills RG: Efficacy of oral GS-4104 in treating acute influenza. ICAAC (1998) 38: LB-4.
58. Aoki F, Osterhaus A, Rimmelzwaan G, Kinnersley N, Ward P: Oral GS-4104 successfully reduces duration and severity of naturally acquired influenza. /CMC (1998) 38: LB-5.
59. Hayden FG, Atmer R, Schilling M, Johnson C, Poretz D, Parr D, Huson L, Ward P, Mills R: Safety and efficacy of oral GS4104 in long-term prophylaxis of natural influenza. ICAAC (1998)38:LB-6.
60. Parvin JD, Moscona A, Pan WT, Leider JM, Palese P: Measurement of the mutation rates of animal viruses: influenza virus and poliovirus type 1. J Vim! (1986) 59:377383.
61. McKimm-Breschkin JL, Blick TJ, Sahasrabudhe A, Tiong T, Marshall D, Hart GJ, Bethell RC, Penn CR: Generation and characterization of variants of NWS/G70C influenza virus after in vitro passage in 4-amino-Neu5Ac2en and 4guanidino-Neu5Ac2en. Antimicrob Agents Chemother (1996) 40:40-46.
62. Penn CR, Bamett JM, Bethell RC, Fenton R, Gearing KL, Healy N, Jowett AJ: Selection of influenza virus with reduced sensitivity in vitro to the neuraminidase inhibitor GG-167 (4-guanidino-Neu5Ac2en): changes in the hemaggiutinin may compensate for loss of neuraminidase activity. In: Options for the control of influenza III, Brown LE, Hampson AW, Webster RG (Eds), Elsevier Science, Amsterdam (1996):735-740.
63. Gubareva LV, Bethell R, Hart GJ, Murti KG, Penn CR, Webster RG: Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidinoNeu5Ac2en. J Virol (1996) 70:1818-1827.
64. Gubareva LV, Matrosovich MN, Brenner MK, Bethell RC, Webster RG: Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J Infect Diseases (1998) 178:1257-1262.
65. Staschke KA, Colacino JM, Baxter AJ, Air GM, Bansal A, Homback WJ, Munroe JE, Laver WG: Molecular basis for the resistance of influenza viruses to 4-guanidino-Neu5Ac2en. Virology (1995) 214:642-646.
66. Colacino JM, Chirgadze NY, Carman E, Murti KG, Loncharich RJ, Baxter AJ, Staschke KA, Laver WG: A single sequence change destabilizes the influenza virus neuraminidase tetramer. Virology (1997) 236:66-75.
67. Varghese JN, Smith PW, Sollis SL, Blick TJ, Sahasrabudhe A, McKimm-Breschkin JL, Colman PM: Drug design against a shifting target: a structural basis for resistance to inhibitors in a variant of influenza virus neuraminidase. Structure (1998) 6:735-746.
68. Gubareva LV, Robinson MJ, Bethell RC, Webster RG: Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4guanidino-neu5Ac2en. J V/ro/(1997) 71:3385-3390.
69. Blick TJ, Tiong T, Sahasrabudhe A, Varghese JN, Colman PM, Hart GJ, Bethell RC, McKimm-Breschkin JL: Generation and characterization of an Influenza virus neuraminidase variant with decreased sensitivity to the neuraminidasespeclfic Inhibitor 4-guanidino-neu5Ac2en. Virology (1995) 214:475-484.
70. McKimm-Breschkin JL, Bethell RC: Substrate and inhibitor interactions with mutant influenza virus neuramindases. Int Antiviral News (1998) 6:147-150.
71. McKimm-Breschkin JL, McDonald M, Blick TJ, Colman PM: Mutation in the influenza virus neuraminidase gene resulting in decreased sensitivity to the neuraminidase inhibitor 4-guanidino-neu5Ac2en leads to instability of the enzyme. Virology (1996) 225:240-242.
72. Sahasrabudhe A. Lawrence L, Epa VC, Varghese JN, Colman PM, McKimm-Breschkin JL: Substrate, inhibitor or antibody stabilizes the Glu119 Gly mutant influenza virus neuraminidase. Virology (1998) 247:14-21.
73. Tai CY, Escarpe PA, Sidwell RW, Williams MA, Lew W, Wu H, Kim CU, Mendel DB: Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS-4071. Antimicrob Agents Chemother (1998) 42:3234-3241.
74. McKimm-Breschkin JL, Sahasrabudhe A, Blick TJ, McDonald M, Colman PM, Hart GJ, Bethell RC, Varghese JN: Mutations in a conserved residue in the influenza virus neuraminidase active site decreases sensitivity to Neu5Ac2en-derived inhibitors. J V//o/(1998) 72:2456-2462.
75. Sudbeck EA, Jedrzejas MJ, Singh S, Brouillette WJ, Air GM, Laver WG, Babu YS, Bantia S, Chand P, Chu N, Montgomery JA, Walsh DA, Luo M: Guanidinobenzoic acid inhibitors of influenza virus neuraminidase. J Mol Biol (1997) 267:584594.
76. Singh S, Jedrzejas MJ, Air GM, Luo M, Laver WG, Brouillette WJ: Structure-based inhibitors of influenza virus sialidase. A benzole acid lead with novel interaction. J Med Chem (1995)38:3217-25.
77. Chànd P, Babu YS, Bantia S, Chu N, Cole LB, Kotian PL, Laver WG, Montgomery JA, Pathak VP, Petty SL, Shrout DP, Walsh DA, Walsh GKl: Design and synthesis of benzole acid derivatives as influenza neuraminidase inhibitors using structure-based drug design. J Med Chem (1997) 40:40304052.
78. Bantia S, Ghate AA, Ananth SL, Babu YS, Air GM, Walsh GM: Generation and characterization of a mutant of influenza A virus selected with the neuraminidase inhibitor BCX-140. Antimicrob Agents Chemother (1998) 42:801-807.
79. Smith PW, Sollid SL, Howes PD, Cherry PC, Starkey ID, Cobley KN, Weston H, Scicinski J, Merritt A, Whittington A, Wyatt P, Taylor N, Green D, Betheil R, Madar S, Fenton RJ, Morley PF, Pateman T, Beresford A: Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 1. Discovery, synthesis, biological activity and structureactivity relationships of 4-guanidino- and 4-amino-4Hpyran-6-carboxamides. J Med Chem (1998) 41 -.787-797.
80. Taylor NR, Cleasby A, Singh O, Skarynski T, Wonacott AJ, SMith PW, Sollis SL, Howes PD, Cherry PC, Bethell R, Colman P, Varghese J: Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 2. Crystallographic and molecular modeling study of complexes of 4-amino-4H-pyran-6carboxamides and sialidase from influenza virus types A and B. J Med Chem (1998) 41:798-807.
81. Chan TH, Xin YC: Synthesis of phosphonic acid analogues of siatic acids (NeuSAc and KDN) as potential sialidase inhibitors. J Org Chem (1997) 62:3500-3504.
82. Sugrue RJ, Hay AJ: Structural characteristics of the M2 protein of the influenza A viruses: evidence that it forms a tetrameric channel. V/ro/ogy (1991) 180:617-624.
83. Pinto LH, Holsinger LJ, Lamb RA: Influenza virus M2 protein has ion channel activity. Cell (1992) 69:517-528.
84. Helenius A: Unpacking the incoming influenza virus. Cell (1992) 69:577-578.
85. Hay AJ: The action of adamantanamines against influenza A viruses: inhibition of the M2 ion channel protein. Semin V7ro/(1992) 3:21-30.
86. Anonymous: Influenza update: influenza B virus now predominates in England and Wales. Commun Dis Hep Wkly (1997) 7:65.
87. Sunstrom NA, Premkumar LS, Premkumar A, Ewart D, Cox GB, Gage PW: Ion channels formed by NB, an influenza B virus protein. J Membrane Biol (1996) 150:127-132.
88. Betts RF: Potential agents in the treatment of influenza. Curr Opin Infect Dis (1992) 5:811-815.
89. Stoof JC, Booij J, Drukarch B: Amantadine as N-methyl aspartic acid receptor antagonist: new possibilities for therapeutic applications? Clin Neurol and Neurosurg (1992) 94 (Suppl):S4-S6.
90. Hayden FG, Huffman HE, Spyler DA: Differences in side effects of amantadine nydrochloride and rimantadine hydrochloride relate to differences in pharmacokinetics. Antimicrob Agents Chemother (1983) 23:458-464.
91. Monto AS. Ohmit SE, Hombuckle K, Pearve CL: Safety and efficacy of long-term use of rimantadine for prophylaxis of type A influenza in nursing homes. Antimicrob Agents Chemother (1995) 39:2224-2228.
92. Hayden F, Belshe RB, Clover RD, Hay AJ, Oakes M, Soo W: Emergence and apparent transmission of rimantadineresistant influenza A virus in families. New Engl J Med (1989)321:1696-1702.
93. Betts RF: Resistance to rimantadine and amantadine. Curr Opin Infect Dis (1991 ) 4:804-808.
94. Hayden FG, Sperber SJ, Belshe RB, Clover RD, Hay AJ, Pyke S: Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine. Antimicrob Agents Chemother (1991) 35:1741-1747.
95. Mast EE, Harmon MW. Gravenstein S, Wu SP, Arden NH, Circo R, Tyszka G, Kendal AP, Davis JP: Emergence and possible transmission of amantadine-resistant viruses during nursing home outbreaks of influenza A (H3N2). Am J Epidemiol (1991 ) 134:988-997.
96. Griffin K, Rader RK, Marino MH, Forgey RW: Novel assay for the influenza virus M2 channel activity. FEBS Lett (1995) 357:269-274.
97. Hahnenberger KM, Krystal M, Esposito K, Tang W, Kurt S: Use of microphysiometry for anr.lysis of heterologous ion channels expressed in yeast Nature Biotechnol (1996) 14:880-883.
98. Wilson IA, Skehel JJ, Wiley DC: Structure of the hemagglutinfn membrane glycoprotein of influenza virus at 3 A resolution. Nature (1981) 289:366-373.
99. Chen J, Lee KH, Steinhauer DA, Stevens DJ, Skehel JJ, Wiley DC: Structure of the hemagglutinin precursor cleavage site, a determinant of influenza pathogenicity and the origin of the labile conformation. Ce//(1998) 95:409-417.
100. Wiley DC, Skehel JJ: The structure and function of the hemagglutinin membrane glycoprotein of influenza virus. Annu Rev Biochem (1987) 56:365-394.
101. Carr CM, Kim PS: Flu virus invasion: halfway there. Science (1994)266:234-236.
102. White JM: Membrane fusion. Science (1992) 258:917-924.
103. Cianci C, Yu KL, Dischino DD, Harte W, Deshpande M, Luo G, Colonno RJ, Meanwell NA, Krystal M: pH-Dependent changes in photoaffinity labeling patterns on the H1 influenza hemagglutinin using an inhibitor of viral fusion. J V/ro/(1999) 73:1785-1794.
104. Nobusawa E, Aoyama T, Kalo H, Suzuki Y, Tateno Y, Nakajima K: Comparison of complete amino acid sequences and receptor-binding properties among 13 serotypes of hemagglutinins of influenza A viruses. V/ro/ogx(1991) 182:475-485.
105. Ishihama A, Nagata K: Viral RNA polymerases. CRC Criti Rev Biochem (1988) 23:27-76.
106. Hsu MT, Parvin JD, Gupta S, Krystal M, Palese P: Genomlc RNAs of influenza viruses are held in a circular conformation in virions and in infected cells by a terminal panhandle. Proc Nati Acad Sei USA (1987) 84:8140-8144.
107. Honda A, Mukaigawa J, Yokoiyama A, Kato A, Ueda S, Nagata K, Krystal M, Nayak DP, Ishihama A: Purification and molecular structure of RNA polymerase from influenza virus A/PR8. J Biochem (1990) 1007:624-628.
108. .. 107. Krug RM, Alonso-Caplen FV, Julkunen l, Katze MG: Expression and replication of the influenza virus genome. In: The Influenza Viruses, Krug RM (Ed), Plenum Press, New York(1989):89-152.
109. Blaas D, Patzelt E, Kuechler E: Cap-recognizing protein of influenza virus. Virology (1982) 116:339-348.
110. Ulmanen I, Broni BA, Krug RM: Role of two influenza virus core P proteins in recognizing cap 1 structures (m7GpppNm) on RNAs and in initiating RNA transcription. Proc Natl Acad Sei USA (1981) 78:7355-7359.
111. Cianci C, Tiley L, Krystal M: Differential activation of the influenza virus polymerase via template RNA binding. J V7ro/(1995) 69:3995-3999.
112. Braam J, Ulmanen l, Krug RM: Molecular model of a eukaryotic transcription complex: Functions and movements of influenza P proteins during capped RNAprimed transcription. Cell (1983) 34:609-618.
113. Krug RM: Priming of influenza viral RNA transcription by capped heterologous RNAs. Curr Top Microbiol Immunol (1981)93:125-150.
114. Plotch SJ, Bouloy M, Ulmanen l, Krug RM: A unique cap (m'GppXm)-dependent influenza virion endonuclease cleaves capped RNAs to generate the primers that initiate viral RNA transcription. Cell (1981) 23:847-858.
115. Hagen M, Chung TOY, Butcher JA, Krystal M: Recombinant Influenza virus polymerase: requirement of both 5' and 3' viral ends for endonuclease activity. J Virol (1994) 68:15091515.
116. Tiley LS, Hagen M, Matthews JT, Krystal M: Sequencespecific binding of the influenza virus RNA polymerase to sequences located at the 5' ends of the viral RNAs. J Virol (1994)68:5108-5116.
117. Cload PA, Hutchinson DW: The inhibition of the RNA polymerase activity of influenza virus A by pyrophosphate analogues. Nucleic Acids Res (1983) 11:5621-5628.
118. Stridh S, Datema R: Mode of interference of trisodium phophonoformate (INN: foscarnet sodium), with influenza virus mRNA synthesis. Virology (1984) 135:293-296.
119. Tisdale M, Ellis M, Klumpp K, Court S, Ford M: Inhibition of influenza virus transcription by 2'-deoxy-2'fluoroguanosine. Antimicrob Agents Chemother (1995) 39:2454-2458.
120. Jakeman KJ, Tisdale M, Russell S, Leone A, Sweet C: Efficacy of 2'-deoxy-2'-fluororibosides against influenza A and B viruses in ferrets. Antimicrob Agents Chemother (1994)38:1864-1867.
121. Hastings JC, Seinick H, Wolanski B, Tomassini JE: Antiinfluenza virus activities of 4-substituted 2,4dioxobutanoic acid inhibitors. Antimicrob Agents Chemother (1996)40:1304-1307.
122. Hensens OD, Goetz MA, Liesch JM, Zink DL, Raghoobar SL, Helms GL, Singh SB: Isolation and structure of flutimide, a novel endonuclease inhibitor of influenza virus. Tetrahedron Lett (1995) 36:2005-2008.
123. Tomassini JE, Davies ME, Hastings JC, Lingham R, Mpjena M, Raghoobar SL, Singh SB, Tkacz JS, Goetz MA: A novel antiviral agent which inhibits the endonuclease of influenza viruses. Antimicrob Agents Chemother (1996) 40:1189-1193.
124. Chung TOY, Ciand C, Hagen M, Terry B, Matthews JT, Krystal M, Colonno RJ: Biochemical studies on capped RNA primers identify a class of oligonudeotide inhibitors of the influenza virus RNA polymerase. Proc Naff Acad Sd USA (1994) 91:23722376.
125. Cianci C, Colonno R, Krystal M: Differential effect of RNA substrates on influenza virus transcription. Virus Res (1997) 50:65-75.
126. Olsen DB, Benseler F, Cole Jl_ Stahlhut MW. DempsW RE, Darke PL, Kuo LC: Elucidation of basic mechanistic and kinetic properties of influenza endonuclease using chemically synthesized RNAs. J Bid Chem (1996) 271:7435-7439.
127. Hatta T, Takai K, Nakada S, Yokota T, Takaku H: Specific inhibition of influenza virus RNA polymerase and nudeoprotein genes expression by liposomally encapsulated antisense phosphorothioate oligonucleotides: penetration and localization of oligonucleotides in clone 76 cells. Biochem Biophys Res Comm (1997) 232:545-549.
128. Luo G, Oanetz S, Krystal M: Inhibition of influenza viral polymerases by minimal viral RNA decoys. J Gen Virol (1997) 79:2329-2333.
129. Ye ZP. Baytor NW, Wagner RR: Transcription-inhibition and RNA-binding domains of influenza A virus matrix protein mapped with anti-jdiotypic antibodies and synthetic peptides. J ViroJ (1989) 63:3586-3594.
130. Nassar EH, Judd AK, Sanchez A, Anastaskxi D, Bücher DJ: Antiviral activity of influenza virus M1 zinc finger peptides. J Virol (1996) 70:8639-8644.
131. Judd AK, Sanchez A, Bucher DJ, Huffman JH, Bailey K, Sidwell RW: In vivo anti-influenza virus activity of a zinc finger peptide. Antimicrob Agents Chemother (1997) 41:687-692.
132. Ovcharenko AV, Zhimov OP: Aprotinin aerosol treatment of Influenza and paramyxovirus bronchopneumonia of mice. Antiviral Res (1994) 23:107-118.
133. j 132. Zürcher T, Luo G, Palese P: Mutations at palmitylation sites of the influenza virus hemagglutinin affect virus formation. J Virol (1994) 68:5748-5754.
134. Sugrue RJ, Belshe RB, Hay AJ: Palmitylation of the influenza A virus M2 protein. Virology (1990) 79:51-56.
135. Muniruzzaman S, Pan YT, Zeng Y, Atkins B, Izumori K, Elbein AD: Inhibition of glycoprotein processing by L-fructose and L-xylulose. G/ycofc/b/opy(1996) 6:795-803.
136. Sidwell RW, Huffman JH, Bailey KW, Wong MH, Nimrod A, Panel A: Inhibitory effects of recombinant manganese Superoxide dismutase on influenza virus infections in mice. Antimicrob Agents Chemother (1996) 40:2626-2631.
137. O'Neill RE, Jaskunas R, Blobel G, Palese P, Moroianu J: Nuclear import of influenza virus RNA can be mediated by viral nucleoprotein and transport factors required for protein import J Biol Chem (1995) 270:22701 -22704.
138. O'Neill RE, Talon J, Palese P: The influenza virus NEP (NS2 protein) mediates the nuclear export of viral ribonucleoproteins. EMBO J(1998) 17:288-296.
139. Lee MG, Kirn KH, Park KY, Kim JS: Evaluation of antiinfluenza effects of camstat in mice infected with nonadapted human influenza viruses. Arch Virol (1996) 141:1979-1989.
140. Zhimov OP, Kirshner LA, Ovcherenko AV, Malyshev NA: Aerosolozed aprotinin is an effective drug against viral respiratory illness. Antiinfect Drugs Chemother (1996) 14:209-216.
141. Ahmad A, Davies J, Randall S, Skinner GRB: Antiviral properties of extract of Opuntia streptacantha. Antiviral Res (1996)30:75-85.
142. Serkedjieva J, Hay AJ: In vitro anti-influenza virus activity of a plant preparation from Geranium sangulneum L. Antiviral Research (199) 37:121-130.
143. Keman MR, Ssndl A, Chen JL, Jolad SD, Blanc P, Murphy JT, Stoddart CA, Nanakom W, Balick MJ, Rozhon EJ: Two new lignans with activity against influenza virus from the medicinal plant Rhinacanthus nasutus. J Nat Prod (1997) 60:635-637.
144. Utsunomiya T, Kobayashi M, Pollard RB, Suzuki F: Glycyrrhizin, an active component of licorice roots, reduces morbidity and mortality of mice infected with lethal doses of influenza virus. Antimicmb Agents Chemother(\997) 41:551-556.
145. Gilbert BE, Wyde PR, Wilson SZ, Meyerson LR: SP-303 small particle aerosol treatment of influenza A virus infection in mice and respiratory syncytial virus infection in cotton rats. Antiviral Res (1993) 21:37-45.
146. Zakey-Rones Z, Varsano N, Zlotnik M, Manor O, Regev L, Schlesinger M, Mumcuoglu M: Inhibition of several strains of influenza virus in vitro and reduction of symptoms by an elderberry extract (Sambucus nlgra L) during an outbreak of Influenza B Panama. J Altem Complement Med (1995) 1:361-369.
147. References to patent literature 201. BioCRYST PHARMACEUTICAL INC (Babu YS, Chand P, Walsh DA): Substituted benzene derivatives useful as neuraminidase inhibitors. WO-09630329 (1996).
148. El Du PONT DE NEMOURS AND Co (Sabesan S): 4-NSubstituted sialic acids and their sialosides. WO-09523157 (1995).
149. BioCRYST PHARMACEUTICALS INC (Bau YS, Chand P, Montgomery JA): Substituted cyclopentane compounds useful as neuraminidase inhibitors. WO-09747194 (1997).
150. SANKYO Co LTD (Honda T, Kobayashi Y, Yamshita M): Neuraminic acid compounds. WO-09806712 (1998).
151. DAIKIN INDUSTRIES LTD (Ohira Y): 4-Substituted-2,7-dideoxy7-fluoro-2,3-didehydrosialic acids. WO-09811093 (1998).
152. BRISTOL MYERS SQUIBB Co (Chung TOY, Cianci C, Hagen M, Krystal M, Colonno RJ): Capped nucleic acid oligomers that inhibit cap-dependent transcription of the influenza virus endonuclease. US-05837852 (1998).